Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer.

This clinical study reports that blood levels of the pro-inflammatory mediator platelet-activating factor (PAF) did not change in colorectal cancer patients. In contrast, plasma levels of two enzymatic activities, one implicated in PAF production (i.e. phospholipase A2) and one in PAF degradation (i...

Descripción completa

Detalles Bibliográficos
Autores principales: Denizot, Yves, Truffinet, Véronique, Bouvier, Stéphane, Gainant, Alain, Cubertafond, Pierre, Mathonnet, Muriel
Formato: Texto
Lenguaje:English
Publicado: 2004
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781534/
https://www.ncbi.nlm.nih.gov/pubmed/15203567
http://dx.doi.org/10.1080/09629350410001664824
Descripción
Sumario:This clinical study reports that blood levels of the pro-inflammatory mediator platelet-activating factor (PAF) did not change in colorectal cancer patients. In contrast, plasma levels of two enzymatic activities, one implicated in PAF production (i.e. phospholipase A2) and one in PAF degradation (i.e. PAF acetylhydrolase activity) were significantly elevated.

Ejemplares similares